Abstract
Dendritic cells (DCs) have traditionally been viewed as constituting an ‘information management’ system that functions solely to integrate a diverse array of incoming signals, in order to induce immune reactivity. In recent years, however, there has been a shift towards viewing these cells as key regulators in the orchestration of immunological tolerance, with increasing recognition that they are capable of suppressing T-cell responses depending on signalling processes and localised biochemical conditions. Indoleamine 2,3-dioxygenase (IDO) competent (IDO+) DCs are a subset of human DCs which are programmed to a tolerogenic state and play a vital role in establishing and maintaining a tumoursuppressing milieu. The expression of IDO in these DCs represents a key mechanism responsible for inducing the tolerogenic state. However, the mechanisms by which IDO becomes dysregulated in this subset of DCs have not yet been described. In this review, the function of IDO+ DCs within the cancer-tolerogenic milieu, as well as the signals responsible for expression of IDO in this subset, will be discussed.
Keywords: Cancer, dendritic cells, immune response, indoleamine 2, 3-dioxygenase, signalling pathways, tolerance
Current Cancer Drug Targets
Title:IDO+ DCs and Signalling Pathways
Volume: 13 Issue: 3
Author(s): Yue Wang, Bao-Hong Yang, Hui Li, Shui Cao, Xiu-Bao Ren and Jin-Pu Yu
Affiliation:
Keywords: Cancer, dendritic cells, immune response, indoleamine 2, 3-dioxygenase, signalling pathways, tolerance
Abstract: Dendritic cells (DCs) have traditionally been viewed as constituting an ‘information management’ system that functions solely to integrate a diverse array of incoming signals, in order to induce immune reactivity. In recent years, however, there has been a shift towards viewing these cells as key regulators in the orchestration of immunological tolerance, with increasing recognition that they are capable of suppressing T-cell responses depending on signalling processes and localised biochemical conditions. Indoleamine 2,3-dioxygenase (IDO) competent (IDO+) DCs are a subset of human DCs which are programmed to a tolerogenic state and play a vital role in establishing and maintaining a tumoursuppressing milieu. The expression of IDO in these DCs represents a key mechanism responsible for inducing the tolerogenic state. However, the mechanisms by which IDO becomes dysregulated in this subset of DCs have not yet been described. In this review, the function of IDO+ DCs within the cancer-tolerogenic milieu, as well as the signals responsible for expression of IDO in this subset, will be discussed.
Export Options
About this article
Cite this article as:
Wang Yue, Yang Bao-Hong, Li Hui, Cao Shui, Ren Xiu-Bao and Yu Jin-Pu, IDO+ DCs and Signalling Pathways, Current Cancer Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/15680096113139990073
DOI https://dx.doi.org/10.2174/15680096113139990073 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluating 3D-printed Bolus Compared to Conventional Bolus Types Used in External Beam Radiation Therapy
Current Medical Imaging Molecular Replacement in Cancer Therapy: Reversing Cancer Metabolic and Mitochondrial Dysfunction, Fatigue and the Adverse Effects of Cancer Therapy
Current Cancer Therapy Reviews Recent Developments in the Chemical Biology of Epothilones
Current Pharmaceutical Design Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Mass Spectrometry Data Analysis in the Proteomics Era
Current Bioinformatics 100% Human Monoclonal Antibodies in Oncology: Hype or Breakthrough?
Current Topics in Medicinal Chemistry Tumor Initiating Cells
Current Pharmaceutical Biotechnology Promises of Apoptosis-Inducing Peptides in Cancer Therapeutics
Current Pharmaceutical Biotechnology Targeted Cancer Therapy; Nanotechnology Approaches for Overcoming Drug Resistance
Current Medicinal Chemistry Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Role of Carbon Monoxide in Kidney Function: Is a little Carbon Monoxide Good for the Kidney?
Current Pharmaceutical Biotechnology Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets Aryl- and Heteroaryl-Thiosemicarbazone Derivatives and Their Metal Complexes: A Pharmacological Template
Recent Patents on Anti-Cancer Drug Discovery Exploration of Metastasis-related Proteins as Biomarkers and Therapeutic Targets in the Treatment of Head and Neck Cancer
Current Cancer Drug Targets Flavonoids for Allergic Diseases: Present Evidence and Future Perspective
Current Pharmaceutical Design Glycosylation Pathways as Drug Targets for Cancer: Glycosidase Inhibitors
Mini-Reviews in Medicinal Chemistry Ghetto Poverty and Pollution in Egypt: A Deadly Threat for Western Countries Caused by New and Infectious Mutants. A Cultural, Social and Microbiological Synopsis
Inflammation & Allergy - Drug Targets (Discontinued) Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors
Current Enzyme Inhibition Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in Epitope Design for Immunotherapy of Cancer
Recent Patents on Anti-Cancer Drug Discovery